Wanbury Ltd.

Wanbury Ltd, A rapidly expanding pharmaceutical company with a significant presence in the global Active Pharmaceutical Ingredients (API) market and domestic branded formulations, has announced its financial results for the fourth quarter and the fiscal year ending March 31, 2024.

Key Financial Highlights (Consolidated) (Rs in Crore)

Particulars Q4 FY24 Q3 FY24 % QoQ Q4 FY23 % YoY  FY24 FY23 % YoY
Revenue from Operations 139.4 145.5 -4.2% 133.0 4.8% 575.6 499.6 15.2%
EBITDA 19.1 21.8 -13% 12.1 57.7% 73.0 24.1 203.1%
EBITDA Margin (%) 13.7% 15.0% -1.3% 9.1% 4.5% 12.7% 4.8% 7.9%
PAT 8.3 10.3 -18.6% 1.0 696% 30.4 (10.4) 392.4%
PAT Margin (%) 6.0% 7.0% -1% 0.8% 5.2% 5.3% (2.1%) 7.3%


Performance Overview

Wanbury Ltd. has demonstrated a notable 15% year-over-year growth in revenue, driven primarily by robust sales of key products such as Metformin and Sertraline. The company’s net profit for Q4FY24 surged by an impressive 696% compared to the same quarter last year, reaching Rs. 8.3 crore. For the full fiscal year 2024, Wanbury reported a net profit of Rs. 30.4 crore, a remarkable turnaround from the previous year’s loss of Rs. 10.4 crore.

Commenting on these results, Mr. Mohan Rayana, Director of Wanbury Ltd., highlighted the company’s strategic focus on niche products and cost optimization measures. “We have achieved significant growth through sales of our key products and by implementing various measures to improve profitability, including operational excellence and yield improvement,” he said.

Future Outlook

Looking ahead, Wanbury Ltd. is optimistic about continuing its growth trajectory. The company plans to expand its customer base, increase the share of business with existing customers, develop new APIs, and enter new therapeutic segments within its formulation business.

For more details, visit Wanbury Ltd. http://www.wanbury.com/

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related News